Breaks Categories: News

FridayNov 11, 2022 11:51 am

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by fatigue, sleep problems and memory issues. “Our team is excited about this milestone in our collaboration with our joint venture…

Continue Reading

FridayNov 11, 2022 11:39 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q3 2022 Financial Report

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (“VECG”) platform for heart attack detection anytime, anywhere, is reporting its financial and operational updates for the third quarter; the quarter ended on Sept. 30, 2022. Included in the report is the fact that the company’s AIMI(TM) platform technology, which is used for diagnosing heart attacks, has been submitted to the U.S Food and Drug Administration (“FDA”) for clearance and the company is on track for initial FDA submission of its AIMIGo(TM) device in the next quarter. Other highlights include that the company broadened…

Continue Reading

ThursdayNov 10, 2022 1:29 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Progress on Clinical Path for CYB004

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced progress on its CYB004-E Phase 1 trial evaluating N,N-dimethyltryptamine (“DMT”). According to the update, dosing has been completed for four out of five participant cohorts, and The Safety Review Committee has confirmed no clinically significant safety or tolerability issues. The trial was acquired from Entheon Biomedical Corp. in July 2022. “The acquisition of the Phase 1 DMT study was done with an eye toward informing and accelerating the clinical path forward for CYB004, and we are very pleased with the progress so far,”…

Continue Reading

ThursdayNov 10, 2022 12:06 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at ‘Exploring the Neuroprotective Qualities of Rare Cannabinoids’ Webinar Event

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announced that its CEO Eric A. Adams and SVP of Preclinical Research and Development Eric Hsu will present at Tribe Public’s upcoming webinar presentation and Q&A event. Titled “Exploring the Neuroprotective Qualities of Rare Cannabinoids,” the event is scheduled to begin at 8:30 a.m. Pacific Time on Nov. 17, 2022. Interested parties should visit https://ibn.fm/5WHrj to register for and join the complimentary, Zoom webinar-based event. Once registered, participants may begin forwarding their questions for InMed’s management to Tribe Public at…

Continue Reading

MondayNov 07, 2022 10:12 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Investment Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, was featured in a recent report published by Zacks Small-Cap Research. In the report, Zacks valued BVXV at $12.00/ADS. The publication reads, “On August 25, 2022, BiondVax Pharmaceuticals Ltd. (BVXV) announced financial results for the second quarter of 2022 and provided a business update. The COVID-19 NanoAb program is proceeding on schedule, with an inhalation proof-of-concept study with the anti-SARS-CoV-2 NanoAb in COVID-19 infected animals expected to begin by the end of 2022. Based on…

Continue Reading

ThursdayNov 03, 2022 1:18 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at RAFT 14 Conference

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that its Head of Technical R&D, Dr. Dalit Weinstein Fischer, will attend and present at Recent Advances in Fermentation Technology (“RAFT”) 14. The conference of the Society for Industrial Microbiology and Biotechnology (“SIMB”) is taking place from Nov. 6 to 9, 2022, in Orlando, Florida. RAFT provides academic and industrial scientists a forum to discuss the latest developments in fermentation technology. Dr. Fischer’s presentation, slated to begin at 3:35 p.m. ET on Nov.…

Continue Reading

ThursdayNov 03, 2022 12:58 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million…

Continue Reading

ThursdayNov 03, 2022 11:16 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

Continue Reading

WednesdayNov 02, 2022 12:45 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Selects POD Group’s Advanced Connectivity Solutions for SmartSole(TM) Platform

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, has selected Pod Group’s ENO ONE IoT SIM cards and advanced connectivity solutions for enterprise IoT applications for its award-winning, two-way GPS SmartSole. A wearable medical monitoring device, SmartSole is integrated into an orthotic insole allowing discreet and unobtrusive tracking and remote monitoring of Alzheimer’s, dementia and autism sufferers. “The POD Group partnership is a critical component for the launch of our SmartSole plus, a mobile hot spot connected to other wearable devices,” said MetAlert CEO Patrick Bertagna. “This level of…

Continue Reading

WednesdayNov 02, 2022 11:53 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

Continue Reading